New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA From The Last 14 Days
Check below for free stories on MEDI;PFE;CELG;PRXL;ACOR;NPSP;ALKS;AZN;TEVA the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | all recent news | >>
April 14, 2014
08:58 EDTACORAcorda Therapeutics delays start of Phase 3 study of dalfampridine-QD to 2H
Acorda Therapeutics announced that the initiation of its Phase 3 study of dalfampridine-QD in people with post-stroke walking deficits will begin in the second half of 2014; previously the company had projected study initiation in the second quarter of 2014. The developer of the once-daily, or QD, formulation has informed the company of an alcohol dose dumping finding in vitro and the company will need to perform a short clinical study to determine whether this also exists in vivo. The clinical study will be conducted in healthy volunteers and is expected to be completed in the third quarter of 2014, Acorda said.
07:56 EDTACORAcorda Therapeutics upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
06:26 EDTACORAcorda Therapeutics upgraded to Outperform from Market Perform at FBR Capital
Subscribe for More Information
06:06 EDTPRXLPAREXEL appoint Peter Steiger as Chief Scientific Officer for Medical Imaging
Subscribe for More Information
April 11, 2014
09:03 EDTCELGCelgene shares can unlock big value, says RBC Capital
Subscribe for More Information
07:19 EDTPFEAcura Pharma to host conference call
Subscribe for More Information
April 10, 2014
10:05 EDTCELGCelgene CEO Hugin says 'excited' about guidance for the year
Subscribe for More Information
10:00 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
08:10 EDTCELGCelgene likely to prevail in patent case, says Stifel
Subscribe for More Information
07:33 EDTCELGCelgene antibody could open door for new area of focus, says Wells Fargo
Wells Fargo believes that Celgene is developing an anti-CD47 antibody that could enable the company to enter the immune-oncology space and pivot into biologics. The firm views the stock as undervalued, and believes that Celgene has many viable opportunities that could enable the stock to rise over the long-term. The firm keeps an Outperform rating on the shares and identifies it as a top pick.
06:17 EDTPFEAcura Pharma announces return of product rights from Pfizer
Subscribe for More Information
05:55 EDTALKSAlkermes upgraded to Buy from Neutral at Mizuho
Subscribe for More Information
<< 1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use